3 Jun 2019 07:01
Yourgene Health plc
("Yourgene Health" or the "Company")
Director's Dealing
Manchester, UK - 3 June 2019: Yourgene Health (AIM: YGEN), the international molecular diagnostics group which commercialises genetic products and services, announces that it was notified on 31 May 2019 that Adam Reynolds, Chairman and a director of the Company, purchased 900,000 ordinary shares of 0.10p each in the Company on 31 May 2019 at a price of 11 pence per ordinary share.
Following the purchase, Mr Reynolds holds 6,349,656 ordinary shares in the Company representing 1.1% of the Company's issued share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Mr Adam Reynolds | ||||
2 | Reason for the notification | |||||
a) | Position/status | Non-Executive Chairman / PDMR | ||||
b) | Initial notification /Amendment | Initial | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Yourgene Health plc | ||||
b) | LEI | 213800UUIT8BZE7QEH33 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a)
| Description of the financial instrument, type of instrument
Identification code
| Ordinary shares of 0.10p each
ISIN: GB00BN31ZD89
| ||||
b) | Nature of the transaction | Direct purchase of shares | ||||
c)
| Price(s) and volume(s) |
| ||||
d)
| Aggregated information - Aggregated volume - Price | N/A | ||||
e) | Date of the transaction | 31 May 2019 | ||||
f) | Place of the transaction | London Stock Exchange | ||||
For more information, please contact:
|
|
Yourgene Health plc Lyn Rees, Chief Executive Officer Barry Hextall, Chief Financial Officer Joanne Cross, Head of Marketing investors@yourgene-health.com
| Tel: +44 (0)161 667 1053
|
Cairn Financial Advisers LLP (Nomad) Liam Murray / James Caithie / Ludovico Lazzaretti
| Tel: +44 (0)20 7213 0880 |
Stifel Nicolaus Europe Limited (Corporate Broker) Nicholas Moore / Matthew Blawat / Ben Maddison
| Tel: +44 (0)20 7710 7600 |
Vigo Communications (PR) Ben Simons / Fiona Henson / Antonia Pollock yourgene@vigocomms.com | Tel: +44 (0)20 7390 0238
|
About Yourgene Health
Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.
Yourgene develops and commercialises simple and accurate molecular diagnostic solutions, primarily for reproductive health. The Group's products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, male infertility tests and genetic disease tests. Yourgene's commercial footprint is already established in the UK, Europe, the Middle East, Africa and Asia.
Our product development, research service and commercial capabilities extend across the lifecycle of genetic test development including regulatory submissions. Through our technical expertise and partnerships, Yourgene Health is also extending its genetic testing offering into oncology.
Yourgene Health is headquartered in Manchester, UK with offices in Taipei and Singapore, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.